Central precocious puberty: Short-term comparative data of treatment with monthly or long-acting three months depot triptorelin

Journal of Pediatric Endocrinology and Metabolism

Volumn 20, Issue SUPPL. 2, 2007, Pages 297-305

  Bertelloni, Silvano ^a   Cassio, Alessandra ^b   Arrigo, Teresa ^c   Wasniewska, Malgorzata ^c   Galluzzi, Fiorella ^d   Einaudi, Silvia ^e   Cappa, Marco ^f   Chiumello, Giuseppe ^g   Bal, Milva ^b   Losi, Stephania ^d   Baroncelli, Giampiero I ^a   Saggese, Giuseppe ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^f BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^g VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Central precocious puberty; GnRH analogs; Monthly triptorelin depot; Puberty suppression; Quarterly triptorelin depot

Indexed keywords

ESTRADIOL; FOLLITROPIN; GONADORELIN; LONG ACTING DRUG; LUTEINIZING HORMONE; TRIPTORELIN;

CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; FEMALE; HOSPITAL ADMISSION; HUMAN; HYPOPHYSIS GONAD SYSTEM; INDIAN; PRECOCIOUS PUBERTY; SCHOOL CHILD; SHORT COURSE THERAPY; TREATMENT DURATION; VAGINA BLEEDING;

EID: 34249892157     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. Partsch C-J, Heger S, Sippell WG. Management and outcome of central precocious puberty. Clin Endocrinol 2002; 56: 129-148.
2. Lahlou N, Carel JC, Chaussain JL, Roger M. Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab 2000; 13 (Suppl 1): 723-737.
3. Brauner R, Adan L, Malandry F, Zantleifer D. Adult height in girls with idiopathic true precocious puberty. J Clin Endocrinol Metab 1994; 79: 415-420.
4. Oostdijk W, Rikken B, Schreuder S, Otten B, Odink R, Rouwè C, Jansen M, Gerver WJ, Waelkens J, Drop S. Final height in central precocious puberty after long-term treatment with a slow-release GnRH agonist. Arch Dis Child 1996; 75: 292-297.
5. Bertelloni S, Baroncelli GI, Sorrentino MC, Perri G, Saggese G. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females. Eur J Pediatr 1998; 157: 363-367.
6. Galluzzi F, Salti R, Bindi G, Pasquini E, La Cauza C. Adult height comparison between boys and girls with precocious puberty after long-term gonadotropin-releasing hormone analogue therapy. Acta Paediatr 1998; 87: 521-527.
7. Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab 1999; 84: 4583-4590.
8. Carel JC, Roger M, Ispas S, Tondu F, Lahlou N, Blumberg J, Chaussain JL. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. J Clin Endocrinol Metab 1999; 84: 1973-1978.
9. Arrigo T, Cisternino M, Galluzzi F, Bertelloni S, Pasquino AM, Antoniazzi F, Borrelli P, Crisafulli G, Wasniewska M, De Luca F. Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. Eur J Endocrinol 1999; 141: 140-144.
10. Carel JC, Lahlou N, Jaramillo O, Montauban V, Teinturier C, Colle M, Lucas C, Chaussain JL. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). J Clin Endocrinol Metab 2002; 87: 4111-4116.
11. Trueman JA, Tillmann V, Cusick CF, Foster P, Patel L, Hall CM, Price DA, Clayton PE. Suppression of puberty with long-acting goserelin (Zoladex-LA): effect on gonadotrophin response to GnRH in the first treatment cycle. Clin Endocrinol 2002; 57: 223-230.
12. Badaru A, Wilson DM, Bachrach LK, Fechner P, Gandrud LM, Durham E, Wintergerst K, Chi C, Klein KO, Neely EK. Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty. J Clin Endocrinol Metab 2006; 91: 1862-1867.
13. Carel JC, Blumberg J, Seymour C, Adamsbaum C, Lahlou N; Triptorelin 3-month CPP Study Group. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty. Eur J Endocrinol 2006; 154: 119-124.
14. Lee PA. Laboratory monitoring of children with precocious puberty. Arch Pediatr Adolesc Med 1994; 148: 369-376.
15. Bouchot O, Sorel JY, Jacqmin D, Lahlou N, Roger M, Blumberg J. Three month sustained release form of triptorelin in patients with advanced prostatic carcinoma: results of an open pharmacodynamic multicenter study. Horm Res 1997; 50: 89-93.
16. Martinez-Aguayo A, Hernandez MI, Beas F, Iniguez G, Avila A, Sovino H, Bravo E, Cassorla F. Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation. J Pediatr Endocrinol Metab 2006; 19: 963-970.
17. Tanner JM, Whitehouse ER. Clinical longitudinal standards for height, weight, height velocity, weight velocity and stages of puberty. Arch Dis Child 1976; 51: 170-179.
18. Greulich WW, Pyle SI. Radiographic Atlas of Skeletal Development of the Hand and Wrist, 2nd Ed. Stanford, CA: Stanford University Press, 1959.
19. Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich and Pyle standards. J Pediatr 1952; 40: 432-441.
20. Tonini G, Lazzerini M. Side effects of GnRH analogue treatment in childhood. J Pediatr Endocrinol Metab 2000; 13 (Suppl 1): 795-803.
21. Heger S, Muller M, Ranke M, Schwarz HP, Waldhauser F, Partsch CJ, Sippell WG. Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function. Mol Cell Endocrinol 2006; 254-255: 217-220.
22. Teillac P, Heyns CF, Kaisary AV, Bouchot O, Blumberg J. Pharmacodynamic equivalence of a decapeptyl 3-month SR formulation with the 28-day SR formulation in patients with advanced prostate cancer. Horm Res 2004; 62: 252-258.
23. Donnez J, Dewart PJ, Hedon B, Perino A, Schindler AE, Blumberg J, Querleu D. Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endometriosis. Fertil Steril 2004; 81: 297-304.
24. Boccardo F, Rubagotti A, Amoroso D, Agostara B, Amadori D, Gallo L, Iacobelli S, Massidda B, Mesiti M, Pacini P, Tomao S, Paganuzzi M, Marroni P. Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients. Cancer Chemother Pharmacol 1999; 43: 461-466.
25. Parker KL, Baens-Bailon RG, Lee PA. Depot leuprolide acetate dosage for sexual precocity. J Clin Endocrinol Metab 1991; 73: 50-52.
26. Yri OE, Bjoro T, Fossa SD. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol 2006; 49: 54-58.
27. Lanes R, Soros A, Jakubowicz S. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs. J Pediatr Endocrinol Metab 2004; 17: 759-766.